Vator,
I certainly don't know how much NWBO will receive for each patient that gets the drug, nor how much any contractor or partner that performs a service on it either, however I believe something in the six digit area will be paid, and the profit to NWBO will be substantial. I cannot imagine them not seeing at least $50K per patient, probably substantially more than that, but even at $50K and DCVax-L becoming part of the SOC for just GBM, I believe worldwide we're looking at blockbuster figures in just a few years.
I don't know the precise number of GBM patients who might be treated worldwide, but let's say for speaking purposes it's 100,000 people. At $50,000 per patient to NWBO with contractors actually doing all the work that's $5 billion in earnings. What's a fair P/E, ten would be on the low side, but that gives us a market cap of $50 billion. Say by then we're up to 2 billion shares outstanding, that's still a $25 share price. I really believe this is very conservative, a P/E of 20 to 30 is far more likely, especially if off label use is expanding and new trials are showing benefits in many cancers for both DCVax-L and Direct.
I believe the above is very conservative, I think they'll make more than $50K a batch, and I also believe this will rapidly grow till well over 100K patients are treated. If over time it's found that other major cancers benefit from our DCVax's these numbers probably expand by a factor of 100 to 1000, but that's to be determined in the future.
If this doesn't make sense to you, or anyone, tell me where I'm wrong, or where I haven't been conservative in my estimate.
Gary
Bullish
Market Data 
Markets 
AI
